|
|
Volumn 22, Issue 19, 2014, Pages 5428-5445
|
|
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists
a
|
|
Author keywords
Aldosterone; Mineralocorticoid receptor; MR; MR antagonists; Nonsteroidal
|
|
Indexed keywords
3 [5 (4 FLUOROPHENYL) 3 METHYL 4 (3 OXO 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 6 YL) 1H PYRAZOL 1 YL]PROPANENITRILE;
6 [1 (2,2 DIFLUORO 3 HYDROXYPROPYL) 5 (4 FLUOROPHENYL) 3 METHYL 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [1 (2,2 DIFLUORO 4 HYDROXYBUTYL) 5 (4 FLUOROPHENYL) 3 METHYL 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [1 (3,3 DIFLUORO 4 HYDROXYBUTYL) 5 (4 FLUOROPHENYL) 3 METHYL 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 1 (3 HYDROXYPROPYL) 3 METHYL 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 1 (4 HYDROXYBUTYL) 3 METHYL 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 1,3 DIMETHYL 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 3 METHYL 1 (PYRIDIN 2 YLMETHYL) 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 3 METHYL 1 (PYRIDIN 3 YLMETHYL) 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 3 METHYL 1 (PYRIDIN 4 YLMETHYL) 1H PYRAZOL 4 YL] 2H 1,4 BENZOXAZIN 3 (4H)ONE;
6 [5 (4 FLUOROPHENYL) 3 METHYL PYRAZOL 4 YL] BENZOXAZIN 3 ONE DERIVATIVE;
ANDROGEN RECEPTOR;
ANTIHYPERTENSIVE AGENT;
EPLERENONE;
GLUCOCORTICOID RECEPTOR;
METHYL GROUP;
MINERALOCORTICOID ANTAGONIST;
N [2 [5 (4 FLUOROPHENYL) 3 METHYL 4 (3 OXO 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 6 YL) 1H PYRAZOL 1 YL]ETHYL]ACETAMIDE;
N [2 [5 (4 FLUOROPHENYL) 3 METHYL 4 (3 OXO 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 6 YL) 1H PYRAZOL 1 YL]ETHYL]METHANESULFONAMIDE;
PROGESTERONE RECEPTOR;
PYRROLE;
SPIRONOLACTONE;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ANTIHYPERTENSIVE ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
BINDING AFFINITY;
BLOOD PRESSURE REGULATION;
CONTROLLED STUDY;
COS 1 CELL LINE;
CRYSTAL STRUCTURE;
DRUG DESIGN;
DRUG POTENCY;
DRUG SCREENING;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
DRUG TARGETING;
HYDROGEN BOND;
HYPERTENSION;
IC50;
IN VITRO STUDY;
LIPOPHILICITY;
MALE;
MEAN RESIDENCE TIME;
MOLECULAR INTERACTION;
NONHUMAN;
ORGAN WEIGHT;
OUTCOME ASSESSMENT;
PROCESS OPTIMIZATION;
RAT;
RECEPTOR BINDING;
SEMINAL VESICLE;
STRUCTURE ACTIVITY RELATION;
SYSTOLIC BLOOD PRESSURE;
|
|
EID: 84907506017
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2014.07.038 Document Type: Article |
|
Times cited : (24)
|
|
References (26)
|
